- Home
- CBUS vs RFL Comparison
CBUS vs RFL Comparison
Compare CBUS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBUS | RFL |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 61.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBUS | RFL |
|---|---|---|
| Price | $2.01 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 371.1K | 78.9K |
| Earning Date | 03-19-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,794,000.00 | $1,029,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $99.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.63 |
| 52 Week Low | $1.09 | $1.12 |
| 52 Week High | $3.40 | $3.19 |
Technical Indicators
Market Signals| Indicator | CBUS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 47.59 |
| Support Level | $1.89 | $1.16 |
| Resistance Level | $2.31 | $1.24 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 53.66 | 46.15 |
Price Performance
Historical ComparisonAbout CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.